FIELD: pharmaceutics.
SUBSTANCE: set of inventions concerning epitope specific for hepatitis B virus (HBV), polynucleotide coding epitope, expression of recombinant vector, recombinant microorganism, virus or cells of mammals, method of producing epitope and method for producing antibody specifically bound to epitope. Described epitope is conservative position HBV, which is not subjected to mutagenesis.
EFFECT: presented group of inventions can be used to obtain compositions with high therapeutic efficiency due to absence of possibility of mutations in used epitope.
22 cl, 8 dwg, 5 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT VACCINE FOR PROPHYLAXIS OF HEPATITIS B (VERSIONS) | 2015 |
|
RU2603729C2 |
| SYSTEMS FOR EXPRESSION OF NEWCASTLE DISEASE VIRUS RECOMBINANT RNA AND VACCINES | 1999 |
|
RU2270864C2 |
| RECOMBINANT Hansenula polymorpha YEAST STRAIN - PRODUCER OF MUTANT HEPATITIS B VIRUS SURFACE ANTIGEN (VERSIONS) | 2015 |
|
RU2586513C1 |
| MUTANT POLYMERASES OF HEPATITIS B VIRUS | 2012 |
|
RU2625021C2 |
| LABELED ANTIGEN E HEPADNAVIRUS AND USE THEREOF IN SCREENING ANTIVIRAL SUBSTANCES | 2015 |
|
RU2711750C2 |
| AGENTS AND METHODS OF TREATING HEPATITIS B VIRUS | 2017 |
|
RU2740802C2 |
| RNA-CONDUCTOR St10 FOR USE IN THE HIGHLY SPECIFIC STREPTOCOCCUS THERMOPHILUS CRISPR / Cas9 (StCas9) NUCLEASES SYSTEM AND USE OF SAID RNA-CONDUCTOR AND StCas9 PROTEIN TO SUPPRESS HEPATITIS B VIRUS EXPRESSION IN THE HOST CELL AND FOR VIRAL DNA ELIMINATION FROM THE HOST CELL | 2018 |
|
RU2694396C1 |
| MUTANT STRAIN OF HEPATITIS B VIRUS AND ITS USING | 1998 |
|
RU2270863C2 |
| EPITOPES OF EPIDERMAL GROWTH FACTOR RECEPTOR SURFACE ANTIGEN AND USE THEREOF | 2013 |
|
RU2650770C2 |
| NUCLEOTIDE SEQUENCE OF CLASSIC SWINE FEVER VIRUS (CSFV) (VARIANTS), POLYPEPTIDE CSFV, PESTOVIRAL VACCINE AGAINST CSFV, DIAGNOSTIC SET AND METHOD | 1995 |
|
RU2201451C2 |
